PURPOSE: To estimate the rate of disease control after conformal radiation therapy using reduced clinical target volume (CTV) margins and to determine factors that predict for tumor progression. METHODS AND MATERIALS: Eighty-eight children (median age, 8.5 years; range, 3.2-17.6 years) received conformal or intensity modulated radiation therapy between 1998 and 2009. The study group included those prospectively treated from 1998 to 2003, using a 10-mm CTV, defined as the margin surrounding the solid and cystic tumor targeted to receive the prescription dose of 54 Gy. The CTV margin was subsequently reduced after 2003, yielding 2 groups of patients: those treated with a CTV margin greater than 5 mm (n=26) and those treated with a CTV margin less than or equal to 5 mm (n=62). Disease progression was estimated on the basis of additional variables including sex, race, extent of resection, tumor interventions, target volume margins, and frequency of weekly surveillance magnetic resonance (MR) imaging during radiation therapy. Median follow-up was 5 years. RESULTS: There was no difference between progression-free survival rates based on CTV margins (>5 mm vs ≤5 mm) at 5 years (88.1% ± 6.3% vs 96.2% ± 4.4% [P=.6386]). There were no differences based on planning target volume (PTV) margins (or combined CTV plus PTV margins). The PTV was systematically reduced from 5 to 3 mm during the time period of the study. Factors predictive of superior progression-free survival included Caucasian race (P=.0175), no requirement for cerebrospinal fluid shunting (P=.0066), and number of surveillance imaging studies during treatment (P=.0216). Patients whose treatment protocol included a higher number of weekly surveillance MR imaging evaluations had a lower rate of tumor progression. CONCLUSIONS: These results suggest that targeted volume reductions for radiation therapy using smaller margins are feasible and safe but require careful monitoring. We are currently investigating the differences in outcome based on host factors to explain the results.
PURPOSE: To estimate the rate of disease control after conformal radiation therapy using reduced clinical target volume (CTV) margins and to determine factors that predict for tumor progression. METHODS AND MATERIALS: Eighty-eight children (median age, 8.5 years; range, 3.2-17.6 years) received conformal or intensity modulated radiation therapy between 1998 and 2009. The study group included those prospectively treated from 1998 to 2003, using a 10-mm CTV, defined as the margin surrounding the solid and cystic tumor targeted to receive the prescription dose of 54 Gy. The CTV margin was subsequently reduced after 2003, yielding 2 groups of patients: those treated with a CTV margin greater than 5 mm (n=26) and those treated with a CTV margin less than or equal to 5 mm (n=62). Disease progression was estimated on the basis of additional variables including sex, race, extent of resection, tumor interventions, target volume margins, and frequency of weekly surveillance magnetic resonance (MR) imaging during radiation therapy. Median follow-up was 5 years. RESULTS: There was no difference between progression-free survival rates based on CTV margins (>5 mm vs ≤5 mm) at 5 years (88.1% ± 6.3% vs 96.2% ± 4.4% [P=.6386]). There were no differences based on planning target volume (PTV) margins (or combined CTV plus PTV margins). The PTV was systematically reduced from 5 to 3 mm during the time period of the study. Factors predictive of superior progression-free survival included Caucasian race (P=.0175), no requirement for cerebrospinal fluid shunting (P=.0066), and number of surveillance imaging studies during treatment (P=.0216). Patients whose treatment protocol included a higher number of weekly surveillance MR imaging evaluations had a lower rate of tumor progression. CONCLUSIONS: These results suggest that targeted volume reductions for radiation therapy using smaller margins are feasible and safe but require careful monitoring. We are currently investigating the differences in outcome based on host factors to explain the results.
Authors: Thomas E Merchant; Erin N Kiehna; Larry E Kun; Raymond K Mulhern; Chenghong Li; Xiaoping Xiong; Frederick A Boop; Robert A Sanford Journal: J Neurosurg Date: 2006-02 Impact factor: 5.115
Authors: Y Uchino; N Saeki; Y Iwadate; T Yasuda; S Konda; T Watanabe; K Wada; I Kazukawa; Y Higuchi; T Iuchi; I Tatsuno; A Yamaura Journal: Endocr J Date: 2000-03 Impact factor: 2.349
Authors: Eugenia P Dolson; Heather M Conklin; Chenghong Li; Xiaoping Xiong; Thomas E Merchant Journal: Pediatr Blood Cancer Date: 2009-07 Impact factor: 3.167
Authors: Jinsoo Uh; Thomas E Merchant; Yimei Li; Xingyu Li; Noah D Sabin; Daniel J Indelicato; Robert J Ogg; Frederick A Boop; John A Jane; Chiaho Hua Journal: Int J Radiat Oncol Biol Phys Date: 2015-05-16 Impact factor: 7.038
Authors: Chiaho Hua; Barry L Shulkin; Daniel J Indelicato; Yimei Li; Xingyu Li; Frederick A Boop; Thomas E Merchant Journal: J Neurosurg Pediatr Date: 2015-08-21 Impact factor: 2.375
Authors: Lisa M Jacola; Jason M Ashford; Wilburn E Reddick; John O Glass; Robert J Ogg; Thomas E Merchant; Heather M Conklin Journal: J Neurooncol Date: 2014-05-22 Impact factor: 4.130
Authors: Hermann L Müller; Maithé Tauber; Elizabeth A Lawson; Jale Özyurt; Brigitte Bison; Juan-Pedro Martinez-Barbera; Stephanie Puget; Thomas E Merchant; Hanneke M van Santen Journal: Nat Rev Dis Primers Date: 2022-04-21 Impact factor: 52.329
Authors: Andrew J Bishop; Brad Greenfield; Anita Mahajan; Arnold C Paulino; M Fatih Okcu; Pamela K Allen; Murali Chintagumpala; Lisa S Kahalley; Mary F McAleer; Susan L McGovern; William E Whitehead; David R Grosshans Journal: Int J Radiat Oncol Biol Phys Date: 2014-07-19 Impact factor: 7.038
Authors: Michael S Rutenberg; Ronny L Rotondo; Dinesh Rao; Adam L Holtzman; Daniel J Indelicato; Soon Huh; Christopher G Morris; William M Mendenhall Journal: J Neurooncol Date: 2020-02-21 Impact factor: 4.130
Authors: Michael S Rutenberg; Adam L Holtzman; Daniel J Indelicato; Soon Huh; Dinesh Rao; Peter J Fiester; Christopher G Morris; Daryoush Tavanaiepour; Robert J Amdur Journal: J Neurooncol Date: 2022-03-12 Impact factor: 4.130